

For More Information

Articles

AMA applauds Senate introduction of medical liability reform legislation. American Medical Association. Press Release, January 10, 2007.

Baicker K, Fisher ES, Chandra A. Malpractice liability costs and the practice of medicine in the Medicare program. *Health Affairs*. 2007; 26:841-852.

Cunningham PJ, Hadley J, Kenney G, Davidoff AJ. Identifying affordable sources of medical care among uninsured persons. *Health Services Research*. 2007; 42:265-285.

DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. *Journal of Health Economics*. 2003; 22:151-185.

Field RI, Plager BJ, Baranowski RA, Healy MA, Longacre ML. Toward a policy agenda on medical research funding: results of a symposium. *Health Affairs*. 2003; 22:224-230. <http://content.healthaffairs.org/cgi/content/full/22/3/224>.

Ginsburg PB, Berenson RA. Revising Medicare's physician fee schedule—much activity, little change. *New England Journal of Medicine*. 2007; 356:1201-1203.

Greenstein, R. Statement on the new report from the Medicare trustees. Center on Budget and Policy Priorities. April 23, 2007.

Hadley, J. Insurance coverage, medical care use, and short-term health changes following an unintentional injury or the onset of a chronic condition. *Journal of the American Medical Association*. 2007; 297:1073-1084.

Kronick R, Rousseau D. Is Medicaid sustainable? Spending projections for the program's second forty years. *Health Affairs*. 2007; 26:271-287. Published online February 23, 2007.

Loscalzo J. The NIH budget and the future of biomedical research, *The New England Journal of Medicine*. 2006; 354:16.

Medicare Advantage advocacy groups see surge in membership. America's Health Insurance Plans. Press Release, May 10, 2007.

Medicare trustees report highlights need for reform; projects steep Medicare physician payment cut. American Medical Association. Press Release, April 23, 2007.

Mello MM, Studdert DM, Schumi J, Brennan TA, Sage WM. Changes in physician supply and scope of practice during a malpractice crisis: evidence from Pennsylvania. *Health Affairs*. 2007;26:w425-w435. Published online 24 April 2007.

Pauly M, Thompson C, Thomas A, Margolis J, Sage W. Who pays? The incidence of high malpractice premiums. *Forum for Health Economics & Policy*. 2006;9(1). Article 2. <http://www.bepress.com/fhep/9/1/2>.

Pham HH, Alexander GC, O'Malley AS. Physician consideration of patients' out-of-pocket costs in making common clinical decisions. *Archives of Internal Medicine*. 2007; 167:663-668.

Schoen C, Doty MM, Collins SR, Holmgren AL. Insured but not protected: how many adults are underinsured? June 14, 2005. *Health Affairs* Web exclusive. W5:289-302.

US Census Bureau. Census Bureau revises 2004 and 2005 health insurance coverage estimates. Press Release, March 23, 2007.

US Department of Health and Human Services. US health care sector moves rapidly to provide consumer information on value. Press Release, May 9, 2007.

Surveys and Reports

AARP Public Policy Institute. *Redefining Medicare's Long-Term Financial Health: A Closer Look at the "Medicare Funding Warning" in the Trustees' Report*. June 2007. <http://www.aarp.org/ppi>.

Access Project. *The Illusion of Coverage: How Health Insurance Fails to Protect People When They Get Sick*. Report. March 2007. http://www.accessproject.org/adobe/the_illusion_of_coverage.pdf.

America's Health Insurance Plans. *January 2007 Census Shows 4.5 Million People Covered by HAS/High-Deductible Health Plans*. A report from the Center for Policy and Research. April 2007.

American Medical Association. *Member Connect Survey: Physicians' Reactions to the Medicare Physician Payment Cuts*. May 2007.

Center for Studying Health System Change. *Medicaid Patients Increasingly Concentrated Among Physicians*. Tracking Report. August 2006.

Center on Budget and Policy Priorities. *A Brief Analysis of the Social Security and Medicare Trustees' Report*. April 23, 2007.

Center on Budget and Policy Priorities. *Private Plan Overpayments Weaken Medicare's Financing and Hasten Program's Insolvency*. April 20, 2007.

Common Good. *Windows of Opportunity: State-Based Ideas for Improving Medical Injury Compensation and Enhancing Patient Safety*. Report. 2006.

Commonwealth Fund. *State Strategies to Expand Health Insurance Coverage: Trends and Lessons for Policymakers*. January 2007.

Congressional Budget Office. *Consumer-Directed Health Plans: Potential Effects on Health Care Spending and Outcomes*. Pub. No. 2585. December 2006.

Congressional Budget Office. *Factors Underlying the Growth in Medicare's Spending for Physicians' Services*. Background Paper. June 2007. Pub. No. 2597.

Congressional Budget Office. H.R. 6134: *Health Opportunity Patient Empowerment Act of 2006*. *Cost Estimate*. September 28, 2006.

Congressional Research Service. *Stem Cell Research: Federal Research Funding and Oversight*. Report to Congress. July 13, 2006.

Donty MM, Edwards, JN, Holmgren AL. *Seeing Red: Americans Driven into Debt by Medical Bills, Results from a National Survey*. Commonwealth Fund, August 2005.

Economic Policy Institute. *Health Insurance Eroding for Working Families*. Briefing Paper #175. September 28, 2006.

Henry J. Kaiser Family Foundation. *Kaiser Health Tracking Poll: Election 2008*. Issue 2, June 2007.

Henry J. Kaiser Family Foundation. *Low Medicaid Spending Growth Amid Rebounding State Revenues: Results from a 50-State Medicaid Budget Survey State Fiscal Years 2006-2007*. October 2006. Pub. No. 7569.

Miller M. *Statement to the House Committee on Energy and Commerce Subcommittee on Health. Improving Medicare Efficiency and Value*. Hearing, April 18, 2007.

National Association of Community Health Centers. *Access Denied: A Look at America's Medically Disenfranchised*. Report. 2007.

National Conference of State Legislatures. *Medical Malpractice Tort Reform. Background*. Updated February 8, 2007. <http://www.ncsl.org/standcomm/sclaw/medmaloverview.htm>.

National Governors' Association. *The Governors Speak—2007: A Report on the State-of-the-State Addresses of the Nation's and U.S. Territories' Governors*. April 2007.

National Institutes of Health. *Summary of the FY 2008 President's Budget*. February 5, 2007. <http://www.nih.gov/about/director/budgetrequest/pressinfofy2008.pdf>.

Neuman P. *Statement to the House, Ways and Means Health Subcommittee, Private Fee-for-Service Plans in Medicare*, May 22, 2007.

Research!America. *America Speaks*, Volume 8. March 2007.

Tufts Center for the Study of Drug Development. *Cost to Develop New Biotech Products Is Estimated to Average \$1.2 Billion*. Impact Report. November/December 2006.

Tufts Center for the Study of Drug Development. *Post-Approval R&D Raises Total Drug Development Costs to \$897 Million*. Impact Report. May/June 2003.

US Food and Drug Administration. *Summary of FDA's FY 2008 Budget*. <http://www.fda.gov/oc/oms/ofm/budget/2008/summary.html>.

US Government Accountability Office. *Consumer-Directed Health Plans: Small but Growing Enrollment Fueled by Rising Cost of Health Care Coverage. Report to the House Chairman on the Budget*. April 2006. GAO-06-514. <http://www.gao.gov/cgi-bin/getrpt?GAO-06-514>.

US Government Accountability Office. *Consumer-Directed Health Plans: Early Enrollee Experiences With Health Savings Accounts and Eligible Health Plans*. August 2006. GAO-06-798. <http://www.gao.gov/cgi-bin/getrpt?GAO-06-798>.

US Government Accountability Office. *Drug Safety: FDA Needs to Further Address Shortcomings in Its Postmarket Decision-Making Process. Testimony to the House Committee on Energy and Commerce, Oversight and Investigations Subcommittee*. March 22, 2007. GAO-07-599T <http://www.gao.gov/cgi-bin/getrpt?GAO-07-599T>.

US Government Accountability Office. *Medicaid Financing: Federal Oversight Initiative Is Consistent with Medicaid Payment Principles But Needs Greater Transparency. Report to the Senate Committee on Finance*. March 2007. GAO-07-214. <http://www.gao.gov/cgi-bin/getrpt?GAO-07-214>.

US Government Accountability Office. *Medicare: Focus on Physician Practice Patterns Can Lead to Greater Program Efficiency*. Report to Congressional Committees. April 2007. GAO-07-307. <http://www.gao.gov/cgi-bin/getrpt?GAO-07-307>.

US Government Accountability Office. *Providing Systematic Feedback to Physicians on Their Practice Patterns Is a Promising Step Toward Encouraging Program Efficiency*. May 10, 2007. GAO-07-862T. <http://www.gao.gov/cgi-bin/getrpt?GAO-07-862T>.

US Government Accountability Office. *The Nation's Long-Term Fiscal Outlook*. April 2007 Update. GAO-07-983R. <http://www.gao.gov/special.pubs/longterm/>.

Wyden R. *Speech on the Senate Floor. Senator Wyden Leads Federal Debate on Health Care Reform*. January 16, 2007.

Fact Sheets and Backgrounders

FamiliesUSA. *Medicare's Phony Problem: The 45 Percent Threshold*. April 2007.

Health Coverage Coalition for the Uninsured. *Expanding Health Care Coverage in the United States: Background Information on a Historic Agreement*. January 18, 2007.

Henry J. Kaiser Family Foundation. *Covering the Uninsured: Growing Need, Strained Resources*. Fact Sheet. January 2007. Pub. No. 7429-02.

Henry J. Kaiser Family Foundation. *Medicare Advantage*. Fact Sheet. March 2007. Pub. No. 2052-09.

Henry J. Kaiser Family Foundation. *Medicare*. Fact Sheet. February 2007. Pub. No. 1066-10.

Henry J. Kaiser Family Foundation. *The Medicaid Program at a Glance*. Fact Sheet. March 2007. Pub. No. 7235-02.

Henry J. Kaiser Family Foundation. *The Uninsured: A Primer*. October 2006. Pub. No. 7451-02.

National Association of Community Health Centers. *America's Health Centers*. Fact Sheet. August 2006.

National Association of Community Health Centers. *Community Health Centers: Centerpiece of President Bush's Vision for Health Care in America*. Undated.

Research!America, *2005 Investment in U.S. Health Research*. Undated.

White House. *Fact Sheet: Advancing Stem Cell Research While Respecting Moral Boundaries*. June 2007.

Namenda

memantine HCl



Tablets/Oral Solution
Rx Only

Brief Summary of Prescribing Information.

For complete details, please see full Prescribing Information for Namenda.

INDICATIONS AND USAGE

Namenda (memantine hydrochloride) is indicated for the treatment of moderate to severe dementia of the Alzheimer's type.

CONTRAINDICATIONS

Namenda (memantine hydrochloride) is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation.

PRECAUTIONS

Information for Patients and Caregivers: Caregivers should be instructed in the recommended administration (twice per day for doses above 5 mg) and dose escalation (minimum interval of one week between dose increases).

Neurological Conditions

Seizures: Namenda has not been systematically evaluated in patients with a seizure disorder. In clinical trials of Namenda, seizures occurred in 0.2% of patients treated with Namenda and 0.5% of patients treated with placebo.

Genitourinary Conditions

Conditions that raise urine pH may decrease the urinary elimination of memantine resulting in increased plasma levels of memantine.

Special Populations

Hepatic Impairment

Namenda undergoes partial hepatic metabolism, with about 48% of administered dose excreted in urine as unchanged drug or as the sum of parent drug and the N-glucuronide conjugate (74%). No dosage adjustment is needed in patients with mild or moderate hepatic impairment. Namenda should be administered with caution to patients with severe hepatic impairment.

Renal Impairment

No dosage adjustment is needed in patients with mild or moderate renal impairment. A dosage reduction is recommended in patients with severe renal impairment (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION in Full Prescribing Information).

Drug-Drug Interactions

N-methyl-D-aspartate (NMDA) antagonists: The combined use of Namenda with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caution.

Effects of Namenda on substrates of microsomal enzymes: *In vitro* studies conducted with marker substrates of CYP450 enzymes (CYP1A2, -2A6, -2C9, -2D6, -2E1, -3A4) showed minimal inhibition of these enzymes by memantine. In addition, *in vitro* studies indicate that at concentrations exceeding those associated with efficacy, memantine does not induce the cytochrome P450 isoenzymes CYP1A2, CYP2C9, CYP2E1, and CYP3A4/5. No pharmacokinetic interactions with drugs metabolized by these enzymes are expected.

Effects of inhibitors and/or substrates of microsomal enzymes on Namenda: Memantine is predominantly renally eliminated, and drugs that are substrates and/or inhibitors of the CYP450 system are not expected to alter the metabolism of memantine.

Acetylcholinesterase (AChE) inhibitors: Coadministration of Namenda with the AChE inhibitor donepezil HCl did not affect the pharmacokinetics of either compound. In a 24-week controlled clinical study in patients with moderate to severe Alzheimer's disease, the adverse event profile observed with a combination of memantine and donepezil was similar to that of donepezil alone.

Drugs eliminated via renal mechanisms: Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. However, coadministration of Namenda and HCTZ/TA did not affect the bioavailability of either memantine or TA, and the bioavailability of HCTZ decreased by 20%. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance® (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide. Furthermore, memantine did not modify the serum glucose lowering effect of Glucovance®.

Drugs that make the urine alkaline: The clearance of memantine was reduced by about 80% under alkaline urine conditions at pH 8. Therefore, alterations of urine pH towards the alkaline condition may lead to an accumulation of the drug with a possible increase in adverse effects. Urine pH is altered by diet, drugs (e.g. carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g. renal tubular acidosis or severe infections of the urinary tract). Hence, memantine should be used with caution under these conditions.

Carcinogenesis, Mutagenesis and Impairment of Fertility

There was no evidence of carcinogenicity in a 113-week oral study in mice at doses up to 40 mg/kg/day (10 times the maximum recommended human dose [MRHD] on a mg/m² basis). There was also no evidence of

carcinogenicity in rats orally dosed at up to 40 mg/kg/day for 71 weeks followed by 20 mg/kg/day (20 and 10 times the MRHD on a mg/m² basis, respectively) through 128 weeks.

Memantine produced no evidence of genotoxic potential when evaluated in the *in vitro* *S. typhimurium* or *E. coli* reverse mutation assay, an *in vitro* chromosomal aberration test in human lymphocytes, an *in vivo* cytogenetics assay for chromosome damage in rats, and the *in vivo* mouse micronucleus assay. The results were equivalent in an *in vitro* gene mutation assay using Chinese hamster V79 cells.

No impairment of fertility or reproductive performance was seen in rats administered up to 18 mg/kg/day (9 times the MRHD on a mg/m² basis) orally from 14 days prior to mating through gestation and lactation in females, or for 60 days prior to mating in males.

Pregnancy

Pregnancy Category B: Memantine given orally to pregnant rats and pregnant rabbits during the period of organogenesis was not teratogenic up to the highest doses tested (18 mg/kg/day in rats and 30 mg/kg/day in rabbits, which are 9 and 30 times, respectively, the maximum recommended human dose [MRHD] on a mg/m² basis).

Slight maternal toxicity, decreased pup weights and an increased incidence of non-ossified cervical vertebrae were seen at an oral dose of 18 mg/kg/day in a study in which rats were given oral memantine beginning pre-mating and continuing through the postpartum period. Slight maternal toxicity and decreased pup weights were also seen at this dose in a study in which rats were treated from day 15 of gestation through the post-partum period. The no-effect dose for these effects was 6 mg/kg, which is 3 times the MRHD on a mg/m² basis.

There are no adequate and well-controlled studies of memantine in pregnant women. Memantine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

It is not known whether memantine is excreted in human breast milk. Because many drugs are excreted in human milk, caution should be exercised when memantine is administered to a nursing mother.

Pediatric Use

There are no adequate and well-controlled trials documenting the safety and efficacy of memantine in any illness occurring in children.

ADVERSE REACTIONS

The experience described in this section derives from studies in patients with Alzheimer's disease and vascular dementia.

Adverse Events Leading to Discontinuation: In placebo-controlled trials in which dementia patients received doses of Namenda up to 20 mg/day, the likelihood of discontinuation because of an adverse event was the same in the Namenda group as in the placebo group. No individual adverse event was associated with the discontinuation of treatment in 1% or more of Namenda-treated patients and at a rate greater than placebo.

Adverse Events Reported in Controlled Trials: The reported adverse events in Namenda (memantine hydrochloride) trials reflect experience gained under closely monitored conditions in a highly selected patient population. In actual practice or in other clinical trials, these frequency estimates may not apply, as the conditions of use, reporting behavior and the types of patients treated may differ. Table 1 lists treatment-emergent signs and symptoms that were reported in at least 2% of patients in placebo-controlled dementia trials and for which the rate of occurrence was greater for patients treated with Namenda than for those treated with placebo. No adverse event occurred at a frequency of at least 5% and twice the placebo rate.

Table 1: Adverse Events Reported in Controlled Clinical Trials in at Least 2% of Patients Receiving Namenda and at a Higher Frequency than Placebo-treated Patients.

Body System Adverse Event	Placebo (N = 922) %	Namenda (N = 940) %
Body as a Whole		
Fatigue	1	2
Pain	1	3
Cardiovascular System		
Hypertension	2	4
Central and Peripheral Nervous System		
Dizziness	5	7
Headache	3	6
Gastrointestinal System		
Constipation	3	5
Vomiting	2	3
Musculoskeletal System		
Back pain	2	3
Psychiatric Disorders		
Confusion	5	6
Somnolence	2	3
Hallucination	2	3
Respiratory System		
Coughing	3	4
Dyspnea	1	2

Other adverse events occurring with an incidence of at least 2% in Namenda-treated patients but at a greater or equal rate on placebo were agitation, fall, inflicted injury, urinary incontinence, diarrhea, bronchitis, insomnia, urinary tract infection, influenza-like symptoms, abnormal gait, depression, upper respiratory tract infection, anxiety, peripheral edema, nausea, anorexia, and arthralgia.

The overall profile of adverse events and the incidence rates for individual adverse events in the subpopulation of patients with moderate to severe Alzheimer's disease were not different from the profile and incidence rates described above for the overall dementia population.

Vital Sign Changes: Namenda and placebo groups were compared with respect to (1) mean change from baseline in vital signs (pulse, systolic blood pressure, diastolic blood pressure, and weight) and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. There were no clinically important changes in vital signs in patients treated with Namenda. A comparison of supine and standing vital sign measures for Namenda and placebo in elderly normal subjects indicated that Namenda treatment is not associated with orthostatic changes.

Laboratory Changes: Namenda and placebo groups were compared with respect to (1) mean change from baseline in various serum chemistry, hematology, and urinalysis variables and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses revealed no clinically important changes in laboratory test parameters associated with Namenda treatment.

ECG Changes: Namenda and placebo groups were compared with respect to (1) mean change from baseline in various ECG parameters and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses revealed no clinically important changes in ECG parameters associated with Namenda treatment.

Other Adverse Events Observed During Clinical Trials

Namenda has been administered to approximately 1350 patients with dementia, of whom more than 1200 received the maximum recommended dose of 20 mg/day. Patients received Namenda treatment for periods of up to 884 days, with 862 patients receiving at least 24 weeks of treatment and 387 patients receiving 48 weeks or more of treatment.

Treatment emergent signs and symptoms that occurred during 8 controlled clinical trials and 4 open-label trials were recorded as adverse events by the clinical investigators using terminology of their own choosing. To provide an overall estimate of the proportion of individuals having similar types of events, the events were grouped into a smaller number of standardized categories using WHO terminology, and event frequencies were calculated across all studies.

All adverse events occurring in at least two patients are included, except for those already listed in Table 1, WHO terms too general to be informative, minor symptoms or events unlikely to be drug-caused, e.g., because they are common in the study population. Events are classified by body system and listed using the following definitions: frequent adverse events - those occurring in at least 1/100 patients; infrequent adverse events - those occurring in 1/100 to 1/1000 patients. These adverse events are not necessarily related to Namenda treatment and in most cases were observed at a similar frequency in placebo-treated patients in the controlled studies.

Body as a Whole: *Frequent:* syncope. *Infrequent:* hypothermia, allergic reaction.

Cardiovascular System: *Frequent:* cardiac failure. *Infrequent:* angina pectoris, bradycardia, myocardial infarction, thrombophlebitis, atrial fibrillation, hypotension, cardiac arrest, postural hypotension, pulmonary embolism, pulmonary edema.

Central and Peripheral Nervous System: *Frequent:* transient ischemic attack, cerebrovascular accident, vertigo, ataxia, hypokinesia. *Infrequent:* paresthesia, convulsions, extrapyramidal disorder, hypertonia, tremor, aphasia, hypoesthesia, abnormal coordination, hemiplegia, hyperkinesia, involuntary muscle contractions, stupor, cerebral hemorrhage, neuralgia, ptosis, neuropathy.

Gastrointestinal System: *Infrequent:* gastroenteritis, diverticulitis, gastrointestinal hemorrhage, melena, esophageal ulceration.

Hemic and Lymphatic Disorders: *Frequent:* anemia. *Infrequent:* leukopenia.

Metabolic and Nutritional Disorders: *Frequent:* increased alkaline phosphatase, decreased weight. *Infrequent:* dehydration, hyponatremia, aggravated diabetes mellitus.

Psychiatric Disorders: *Frequent:* aggressive reaction. *Infrequent:* delusion, personality disorder, emotional lability, nervousness, sleep disorder, libido increased, psychosis, amnesia, apathy, paranoid reaction, thinking abnormal, crying abnormal, appetite increased, paroniria, delirium, depersonalization, neurosis, suicide attempt.

Respiratory System: *Frequent:* pneumonia. *Infrequent:* apnea, asthma, hemoptysis.

Skin and Appendages: *Frequent:* rash. *Infrequent:* skin ulceration, pruritus, cellulitis, eczema, dermatitis, erythematous rash, alopecia, urticaria.

Special Senses: *Frequent:* cataract, conjunctivitis. *Infrequent:* macula lutea degeneration, decreased visual acuity, decreased hearing, tinnitus, blepharitis, blurred vision, corneal opacity, glaucoma, conjunctival hemorrhage, eye pain, retinal hemorrhage, xerophthalmia, diplopia, abnormal lacrimation, myopia, retinal detachment.

Urinary System: *Frequent:* frequent micturition. *Infrequent:* dysuria, hematuria, urinary retention.

Events Reported Subsequent to the Marketing of Namenda, both US and Ex-US

Although no causal relationship to memantine treatment has been found, the following adverse events have been reported to be temporally associated with memantine treatment and are not described elsewhere in labeling: aspiration pneumonia, asthenia, atrioventricular block, bone fracture, carpal tunnel syndrome, cerebral infarction, chest pain, cholelithiasis, claudication, colitis, deep venous thrombosis, depressed level of consciousness (including loss of consciousness and rare reports of coma), dyskinesia, dysphagia, encephalopathy, gastritis, gastroesophageal reflux, grand mal convulsions, intracranial hemorrhage, hepatitis (including increased ALT and AST and hepatic failure), hyperglycemia, hyperlipidemia, hypoglycemia, ileus, increased INR, impotence, lethargy, malaise, myoclonus, neuroleptic malignant syndrome, acute pancreatitis, Parkinsonism, acute renal failure (including increased creatinine and renal insufficiency), prolonged QT interval, restlessness, sepsis, Stevens-Johnson syndrome, suicidal ideation, sudden death, supraventricular tachycardia, tachycardia, tardive dyskinesia, thrombocytopenia, and hallucinations (both visual and auditory).

ANIMAL TOXICOLOGY

Memantine induced neuronal lesions (vacuolation and necrosis) in the multipolar and pyramidal cells in cortical layers III and IV of the posterior cingulate and retrosplenial neocortices in rats, similar to those which are known to occur in rodents administered other NMDA receptor antagonists. Lesions were seen after a single dose of memantine. In a study in which rats were given daily oral doses of memantine for 14 days, the no-effect dose for neuronal necrosis was 6 times the maximum recommended human dose on a mg/m² basis. The potential for induction of central neuronal vacuolation and necrosis by NMDA receptor antagonists in humans is unknown.

DRUG ABUSE AND DEPENDENCE

Controlled Substance Class: Memantine HCl is not a controlled substance.

Physical and Psychological Dependence: Memantine HCl is a low to moderate affinity uncompetitive NMDA antagonist that did not produce any evidence of drug-seeking behavior or withdrawal symptoms upon discontinuation in 2,504 patients who participated in clinical trials at therapeutic doses. Post marketing data, outside the U.S., retrospectively collected, has provided no evidence of drug abuse or dependence.

OVERDOSAGE

Signs and symptoms associated with memantine overdose in clinical trials and from worldwide marketing experience include agitation, confusion, ECG changes, loss of consciousness, psychosis, restlessness, slowed movement, somnolence, stupor, unsteady gait, visual hallucinations, vertigo, vomiting, and weakness. The largest known ingestion of memantine worldwide was 2.0 grams in a patient who took memantine in conjunction with unspecified antidiabetic medications. The patient experienced coma, diplopia, and agitation, but subsequently recovered.

Because strategies for the management of overdose are continually evolving, it is advisable to contact a poison control center to determine the latest recommendations for the management of an overdose of any drug.

As in any cases of overdose, general supportive measures should be utilized, and treatment should be symptomatic. Elimination of memantine can be enhanced by acidification of urine.



FOREST PHARMACEUTICALS, INC.
Subsidiary of Forest Laboratories, Inc.
St. Louis, Missouri 63045

Licensed from Merz Pharmaceuticals GmbH

Rev. 04/07

© 2007 Forest Laboratories, Inc.

Treat today

A day well spent— proven efficacy with excellent tolerability



- Improves function, delays onset of behavioral symptoms, and provides benefits in cognition¹⁻³
- Excellent safety and tolerability with low risk of unpleasant gastrointestinal side effects^{4,5}
- May reduce care dependence and caregiver distress^{3,6}
- Proven effective first-line and in combination with an acetylcholinesterase inhibitor^{1,2}

Preferred status on the majority of health plan and Medicare Part D formularies¹

NAMENDA® (memantine HCl) is indicated for the treatment of moderate to severe Alzheimer's disease.

NAMENDA is contraindicated in patients with known hypersensitivity to memantine HCl or any excipients used in the formulation. The most common adverse events reported with NAMENDA vs placebo ($\geq 5\%$ and higher than placebo) were dizziness, confusion, headache, and constipation. In patients with severe renal impairment, the dosage should be reduced.

References: 1. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ, for the Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. *N Engl J Med.* 2003;348:1333-1341. 2. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, for the Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. *JAMA.* 2004;291:317-324. 3. Cummings JL, Schneider E, Tariot PN, Graham SM, for the Memantine MEM-MD-02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. *Neurology.* 2006;67:57-63. 4. Data on file. Forest Laboratories, Inc. 5. NAMENDA® (memantine HCl) Prescribing Information. Forest Pharmaceuticals, Inc., St Louis, Mo. 6. Winblad B, Pontis N. Memantine in severe dementia: results of the "M-BEST Study" (Benefit and efficacy in severely demented patients during treatment with memantine). *Int J Geriatr Psychiatry.* 1999;14:135-146.

Namenda
memantine HCl 
Extending memory and function

 Forest Pharmaceuticals, Inc.
Pharmaceuticals • Therapeutics • Healthcare • Biotech • Medical Devices • Specialty Drugs

For more details, please visit www.namenda.com.
Please see brief summary of Prescribing Information on the adjacent pages.